Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class Of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.